Although currently available DPP4 inhibitors have good safety and tolerability [36], and most patients have only mild adverse reactions, there is interest in dietary therapies for diabetes that have relatively low efficacy but no adverse reactions. This evidence concerns the gene DPP4 and diabetes mellitus.